Calcitonin geneg related peptide does not cause the familial hemiplegic migraine phenotype

Neurology

Volumn 71, Issue 11, 2008, Pages 841-847

  Hansen, Jakob Møller ^a,b   Thomsen, Lise Lykke ^b   Olesen, Jes ^a   Ashina, Messoud ^a  

^a Danish Headache Center   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CYCLIC AMP;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED STUDY; DISEASE SEVERITY; FAMILIAL HEMIPLEGIC MIGRAINE; FEMALE; GENE; GENE MUTATION; GENOTYPE; HEADACHE; HUMAN; INCIDENCE; MALE; MIDDLE CEREBRAL ARTERY; PAIN ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SUPERFICIAL TEMPORAL ARTERY; BLOOD FLOW VELOCITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; MIGRAINE WITH AURA; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SINGLE BLIND PROCEDURE;

ADULT; BLOOD FLOW VELOCITY; CALCITONIN GENE-RELATED PEPTIDE; CYCLIC AMP; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE WITH AURA; MUTATION; PHENOTYPE; SIGNAL TRANSDUCTION; SINGLE-BLIND METHOD;

EID: 53049110894     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000325482.64106.3f     Document Type: Article

References (38)

1. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543-552.
2. De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump α2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003;33:192-196.
3. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005;366:371-377.
4. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24 (suppl 1):9-160.
5. Thomsen LL, Eriksen MK, Roemer SF, et al. A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria. Brain 2002;125:1379-1391.
6. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-196.
7. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-187.
8. Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004;500:315-330.
9. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54-61.
10. Olesen J, Diener HC, Husstedt IW, etal. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350: 1104-1110.
11. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-1312.
12. Thomsen LL, Kirchmann M, Bjornsson A, et al. The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain 2007;130:346-356.
13. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache: basic characteristics. Pain 1989;38:17-24.
14. Thomsen LL, Iversen HK. Experimental and biological variation of three-dimensional transcranial Doppler measurements. J Appl Physiol 1993;75:2805-2810.
15. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. Lancet 1990;336: 837-839.
16. Petersen KA, Lassen LH, Birk S, et al. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 2005;77:202-213.
17. Altman DG. Statistics in Practice. London: BMJ, 1982: 6-8.
18. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300:230-235.
19. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004;41:701-710.
20. Hansen JM, Thomsen L, Olesen J, AshinaM. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia 2008;28:496-505.
21. Hansen JM, Thomsen LL, Marconi R, et al. Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia 2008;28:367-375.
22. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981;9:344-352.
23. Moskowitz MA, Bolay H, Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann Neurol 2004;55:276-280.
24. Dreier JP, Kleeberg J, Petzold G, et al. Endothelin-1 potently induces Leao's cortical spreading depression in vivo in the rat: a model for an endothelial trigger of migrainous aura? Brain 2002;125:102-112.
25. Kleeberg J, Petzold GC, Major S, et al. ET-1 induces cortical spreading depression via activation of the ETA receptor/phospholipase C pathway in vivo. Am J Physiol Heart Circ Physiol 2004;286:H1339-H1346.
26. Drissi H, Lasmoles F, Le Mellay V, et al. Activation of phospholipase C-β1 via Gaq/11 during calcium mobilization by calcitonin gene-related peptide. J Biol Chem 1998;273: 20168-20174.
27. Salmon AM, Damaj MI, Marubio LM, et al. Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice. Nat Neurosci 2001;4:357-358.
28. Dalkara T, Zervas NT, Moskowitz MA. From spreading depression to the trigeminovascular system. Neurol Sci 2006;27 (suppl 2):S86-S90.
29. Mogil JS, Miermeister F, Seifert F, et al. Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc Natl Acad Sci USA 2005;102: 12938-12943.
30. Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neu-rol 2005;58:698-705.
31. Thomsen LL, Iversen HK, Brinck TA, Olesen J. Arterial su-persensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia 1993;13:395-399.
32. Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005;25:139-147.
33. Lykke Thomsen L, Kirchmann Eriksen M, Faerch Romer S, et al. An epidemiological survey of hemiplegic migraine. Cephalalgia 2002;22:361-375.
34. Arulmani U, Gupta S, Maassenvandenbrink A, et al. Experimental migraine models and their relevance in migraine therapy. Cephalalgia 2006;26:642-659.
35. Christiansen I, Thomsen LL, Daugaard D, et al. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 1999;19:660-667.
36. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 2004;110:675-680.
37. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1994;1:73-80.
38. de Vries B, Freilinger T, Vanmolkot KR, et al. Systematic analysis of three FHM genes in 39 sporadic patients with hemiplegic migraine. Neurology 2007;69:2170- 2176.